Bliss GVS Pharma Limited — Important, 15-04-2025: Updates

Rising Pharma Holdings, Inc., a partner of Bliss GVS Pharma Limited, has received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Mesalamine Suppositories 1000 mg. This product is projected to have a U.S. market size of approximately USD 29 million for the year ending January 2025, indicating significant potential for revenue generation. The approval enhances Bliss GVS Pharma's portfolio of differentiated OTC and prescription products, leveraging its established R&D capabilities. This milestone strengthens the company's position in the competitive U.S. market and could provide a positive outlook for growth and operational expansion in this sector.